Tìm theo
Doxycycline
Các tên gọi khác (12 ) :
  • (4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
  • 5-Hydroxy-alpha-6-deoxytetracycline
  • 6-alpha-deoxy-5-oxytetracycline
  • 6alpha-Deoxy-5-oxytetracycline
  • 6α-deoxy-5-oxytetracycline
  • Doxiciclina
  • Doxycyclin
  • Doxycycline (anhydrous)
  • Doxycyclinum
  • Jenacyclin
  • Supracyclin
  • Vibramycin
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 564-25-0
ATC: A01AB22, J01AA02
ĐG : Actavis Group , http://www.actavis.com
CTHH: C22H24N2O8
PTK: 444.4346
A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum). [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C22H24N2O8
Phân tử khối
444.4346
Monoisotopic mass
444.153265754
InChI
InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
InChI Key
InChIKey=JBIWCJUYHHGXTC-AKNGSSGZSA-N
IUPAC Name
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
Traditional IUPAC Name
doxycycline
SMILES
[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
Độ tan chảy
201 °C
Độ hòa tan
630 mg/L (at 25 °C)
logP
-0.02
logS
-2.87
pKa (strongest acidic)
-2.2
pKa (Strongest Basic)
7.75
PSA
181.62 Å2
Refractivity
113.89 m3·mol-1
Polarizability
42.88 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
9
H Bond Donor Count
6
Physiological Charge
-1
Number of Rings
4
Bioavailability
1
Dược Lực Học : Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis.
Cơ Chế Tác Dụng : A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum). [PubChem] Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the apicoplast of Plasmodium falciparum, a malaria causing organism.
Dược Động Học :
▧ Absorption :
Completely absorbed following oral administration.
▧ Protein binding :
>90%
▧ Metabolism :
Hepatic
▧ Route of Elimination :
They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.
▧ Half Life :
18-22 hours
Độc Tính : Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD50=262 mg/kg (I.P. in rat).
Chỉ Định : Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus
Tương Tác Thuốc :
  • Acenocoumarol The tetracycline, doxycycline, may increase the anticoagulant effect of acenocoumarol.
  • Acitretin Increased risk of intracranial hypertension
  • Aluminium Formation of non-absorbable complexes
  • Amobarbital The anticonvulsant, amobarbital, decreases the effect of doxycycline.
  • Amoxicillin Possible antagonism of action
  • Ampicillin Possible antagonism of action
  • Anisindione The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione.
  • Aprobarbital The anticonvulsant, aprobarbital, decreases the effect of doxycycline.
  • Attapulgite Formation of non-absorbable complexes
  • Azlocillin Possible antagonism of action
  • Aztreonam Possible antagonism of action
  • Bacampicillin Possible antagonism of action
  • Benzylpenicillin Possible antagonism of action
  • Bexarotene Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
  • Butabarbital The anticonvulsant, butabarbital, decreases the effect of doxycycline.
  • Butalbital The anticonvulsant, butalbital, decreases the effect of doxycycline.
  • Butethal The anticonvulsant, butethal, decreases the effect of doxycycline.
  • Calcium Formation of non-absorbable complexes
  • Calcium Acetate Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
  • Calcium Chloride Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
  • Carbamazepine The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline.
  • Carbenicillin Possible antagonism of action
  • Clavulanate Possible antagonism of action
  • Cloxacillin Possible antagonism of action
  • Colesevelam Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
  • Cyclacillin Possible antagonism of action
  • Dicloxacillin Possible antagonism of action
  • Dicoumarol The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol.
  • Dihydroquinidine barbiturate The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline.
  • Ethinyl Estradiol Doxycycline may decrease the contraceptive effect of ethinyl estradiol.
  • Ethotoin The anticonvulsant, ethotoin, decreases the effect of doxycycline.
  • Etretinate Increased risk of intracranial hypertension
  • Flucloxacillin Possible antagonism of action
  • Fosphenytoin The anticonvulsant, fosphenytoin, decreases the effect of doxycycline.
  • Heptabarbital The anticonvulsant, heptabarbital, decreases the effect of doxycycline.
  • Hetacillin Possible antagonism of action
  • Hexobarbital The anticonvulsant, hexobarbital, decreases the effect of doxycycline.
  • Iron Formation of non-absorbable complexes
  • Iron Dextran Formation of non-absorbable complexes
  • Isotretinoin Increased risk of intracranial hypertension
  • Magnesium Formation of non-absorbable complexes
  • Magnesium oxide Formation of non-absorbable complexes
  • Mephenytoin The anticonvulsant, mephenytoin, decreases the effect of doxycycline.
  • Mestranol This anti-infectious agent could decrease the effect of the oral contraceptive
  • Methohexital The anticonvulsant, methohexital, decreases the effect of doxycycline.
  • Methotrexate The tetracycline, doxycycline, may increase methotrexate toxicity.
  • Methylphenobarbital The anticonvulsant, methylphenobarbital, decreases the effect of doxycycline.
  • Meticillin Possible antagonism of action
  • Mezlocillin Possible antagonism of action
  • Nafcillin Possible antagonism of action
  • Oxacillin Possible antagonism of action
  • Penicillin V Possible antagonism of action
  • Pentobarbital The anticonvulsant, pentobarbital, decreases the effect of doxycycline.
  • Phenobarbital The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline.
  • Phenytoin The anticonvulsant, phenytoin, may decrease the effect of doxycycline.
  • Piperacillin Possible antagonism of action
  • Pivampicillin Possible antagonism of action
  • Pivmecillinam Possible antagonism of action
  • Primidone The anticonvulsant, primidone, decreases the effect of doxycycline.
  • Quinidine barbiturate The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline.
  • Rifabutin The rifamycin decreases the effect of doxycycline
  • Rifampicin The rifamycin decreases the effect of doxycycline
  • Secobarbital The anticonvulsant , secobarbital, decreases the effect of doxycycline.
  • Talbutal The anticonvulsant, talbutal, decreases the effect of doxycycline.
  • Tamsulosin Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed.
  • Tazobactam Possible antagonism of action
  • Thiopental Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered.
  • Ticarcillin Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline.
  • Tolterodine Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
  • Tretinoin Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
  • Warfarin The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin.
  • Zinc Formation of non-absorbable complexes
Liều Lượng & Cách Dùng : Capsule - Oral
Gel, metered - Periodontal
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Adoxa
  • Công ty :
    Sản phẩm biệt dược : Alodox
  • Công ty : Atrix
    Sản phẩm biệt dược : Atridox
  • Công ty : Mayne
    Sản phẩm biệt dược : Doryx
  • Công ty : Galpharma
    Sản phẩm biệt dược : Doxy
  • Công ty : Laboratoire Riva
    Sản phẩm biệt dược : Doxycin
  • Công ty : Actavis
    Sản phẩm biệt dược : Doxylin
  • Công ty :
    Sản phẩm biệt dược : Jenacyclin
  • Công ty : Micro Labs
    Sản phẩm biệt dược : Microdox
  • Công ty : Watson
    Sản phẩm biệt dược : Monodox
  • Công ty :
    Sản phẩm biệt dược : Morgidox
  • Công ty :
    Sản phẩm biệt dược : NicAzelDoxyKit
  • Công ty : Nu-Pharm
    Sản phẩm biệt dược : Nu-Doxycycline
  • Công ty :
    Sản phẩm biệt dược : Ocudox
  • Công ty : Galderma
    Sản phẩm biệt dược : Oracea
  • Công ty : Alliance
    Sản phẩm biệt dược : Periostat
  • Công ty : Grünenthal
    Sản phẩm biệt dược : Supracyclin
  • Công ty : Pfizer
    Sản phẩm biệt dược : Vibra-Tabs
  • Công ty : Pfizer
    Sản phẩm biệt dược : Vibramycin
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00254
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=5281011
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506491
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C06973
ChemSpider
http://www.chemspider.com/Chemical-Structure.4444486.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50041429
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/49884-091-01
PharmGKB
http://www.pharmgkb.org/drug/PA449415
Wikipedia
http://en.wikipedia.org/wiki/Doxycycline
RxList
http://www.rxlist.com/cgi/generic/doxycyc.htm
Drugs.com
http://www.drugs.com/doxycycline.html
... loading
... loading